CDRH launches transparency site

The FDA's Center for Devices and Radiological Health this week launched its website to provide information about medical device and radiation-emitting product regulatory processes and decisions as part of the agency's transparency initiative. "The Center for Devices and Radiological Health Transparency website gives the public a window into our work," says CDRH Director Jeffrey Shuren in a statement. "It provides a closer and clearer look at what we do and why we do it."

CDRH's previous site provided information about approved products, industry guidance, medical device safety and adverse event reports; it now will include additional information displayed in a more user-friendly format. The updated site includes information related to the following topics:

  • Premarket submissions for approved and cleared products--summaries of the FDA's review of the documents and data that companies submit to the agency when requesting clearance or approval to market a new or improved device, and the systems the FDA uses to evaluate these submissions;

  • Postmarket performance and safety--documents and data describing how well devices perform after they are on the market, and information about how the FDA monitors medical device safety;

  • Compliance and enforcement--official actions that the FDA has taken in response to problems with devices or device companies;

  • Science and research--research programs at CDRH or sponsored by CDRH;

  • Educational resources--information to help industry and others understand CDRH requirements and processes; and

  • CDRH performance data--metrics about CDRH programs.

The site also features a searchable Total Product Life Cycle database, which integrates premarket and postmarket medical device information from multiple data sources into a single snapshot.

In the coming months, the FDA will expand the CDRH Transparency website to include premarket approval and clearance reviews. It also includes a feedback feature that will allow the FDA to collect input and suggestions from the public about the information provided.

- see the CDRH announcement

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.